Migdal Insurance & Financial Holdings Ltd. Has $2.26 Million Stake in Johnson & Johnson (NYSE:JNJ)

Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 281.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 14,436 shares of the company's stock after acquiring an additional 10,653 shares during the quarter. Migdal Insurance & Financial Holdings Ltd.'s holdings in Johnson & Johnson were worth $2,261,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Tower View Wealth Management LLC raised its stake in shares of Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company's stock worth $40,000 after buying an additional 165 shares in the last quarter. Keener Financial Planning LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $40,000. Creative Capital Management Investments LLC lifted its holdings in shares of Johnson & Johnson by 43.0% during the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company's stock valued at $45,000 after purchasing an additional 86 shares during the last quarter. Altshuler Shaham Ltd lifted its holdings in shares of Johnson & Johnson by 37.8% during the third quarter. Altshuler Shaham Ltd now owns 317 shares of the company's stock valued at $49,000 after purchasing an additional 87 shares during the last quarter. Finally, Mizuho Securities Co. Ltd. lifted its holdings in shares of Johnson & Johnson by 216.7% during the third quarter. Mizuho Securities Co. Ltd. now owns 380 shares of the company's stock valued at $59,000 after purchasing an additional 260 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.3 %

JNJ stock traded up $0.44 during mid-day trading on Tuesday, hitting $149.56. The stock had a trading volume of 9,074,728 shares, compared to its average volume of 7,354,235. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The company has a fifty day moving average of $155.83 and a 200 day moving average of $155.51. The stock has a market capitalization of $360.41 billion, a price-to-earnings ratio of 9.32, a PEG ratio of 2.44 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts' consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The firm's revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.68 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. Johnson & Johnson's dividend payout ratio is currently 29.68%.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm's stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company's stock, valued at approximately $22,099,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm's stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company's stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Morgan Stanley reduced their target price on Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating for the company in a report on Wednesday, April 17th. Raymond James upped their target price on Johnson & Johnson from $172.00 to $175.00 and gave the company an "outperform" rating in a report on Wednesday, January 3rd. HSBC raised Johnson & Johnson from a "hold" rating to a "buy" rating and upped their target price for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Royal Bank of Canada reduced their price objective on Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 17th. Finally, StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $175.86.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.